Bayer's recent drug launches and diverse operations support steady growth.
Bayer reported excellent cardiovascular data for Xarelto, and we are increasing our peak sales for the drug (as reported by Bayer) by EUR 2.5 billion to EUR 7.9 billion, which increases our Bayer fair value estimate by 5%. We continue to view the stock as undervalued. Also, while the news is positive for Johnson & Johnson, which holds partial rights to the drug in the U.S., the higher peak sales number doesn’t materially alter our fair value estimate for that firm. However, for both firms, t...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.